Table 1.

Clinical, pathologic, and survival characteristics of the 44 NMIBC

Whole populationNo recurrenceRecurrenceMuscle-invasive progression
Number of patients (%)Number (%)Number (%)P valueaNumber (%)P valueb
Total population44 (100.0)14 (31.8)22 (50.0)8 (18.2)
Age (years)
 ≥6034 (77.3)10 (29.4)16 (47.1)0.778 (23.5)0.17
 <6010 (22.7)4 (40.0)6 (60.0)0 (0.0)
Sex
 Male41 (93.2)13 (31.7)20 (48.8)>0.998 (19.5)>0.99
 Female3 (6.8)1 (33.3)2 (66.7)0 (0.0)
Smoking status
 Nonsmoker19 (43.2)4 (21.1)12 (63.2)0.133 (15.8)0.97
 Smoker25 (56.8)10 (40.0)10 (40.0)5 (20.0)
History of NMIBC
 No24 (54.5)11 (45.8)10 (41.7)0.0493 (12.5)0.50
 Yes20 (45.5)3 (15.0)12 (60.0)5 (25.0)
Associated pTis
 No42 (95.4)14 (33.3)22 (52.4)NAc6 (14.3)0.030
 Yes2 (4.6)0 (0.0)0 (0.0)2 (100)
Grade
 Low grade20 (45.5)9 (45.0)10 (50.0)0.271 (5.0)0.094
 High grade24 (54.5)5 (20.8)12 (50.0)7 (29.2)
Tumor stage
 Ta30 (68.2)10 (33.3)18 (60.0)0.752 (6.7)0.008
 T114 (31.8)4 (28.6)4 (28.6)6 (42.9)
FGFR3 status
 Mutated22 (50.0)5 (22.7)16 (72.7)0.0281 (4.5)0.051
 Not mutated22 (50.0)9 (40.9)6 (27.3)7 (31.8)
PIK3CA status
 Mutated7 (15.9)4 (57.1)2 (28.6)0.181 (14.3)>0.99
 Not mutated37 (84.1)10 (27.0)20 (54.1)7 (18.9)
  • NOTE: P < 0.05 are in bold.

  • aχ2 test, χ2 test with Yates' correction, or Fisher test if appropriate (recurrence vs. no recurrence).

  • bχ2 test, Yates's χ2 test, or Fisher test if appropriate (muscle-invasive progression vs. others).

  • cNot applicable.